Merck KGaA (MRK) PT Set at €99.00 by Deutsche Bank AG

Merck KGaA (FRA:MRK) has been given a €99.00 ($115.12) price objective by stock analysts at Deutsche Bank AG in a research report issued to clients and investors on Friday. The firm presently has a “neutral” rating on the healthcare company’s stock. Deutsche Bank AG’s target price suggests a potential upside of 10.26% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Kepler Capital Markets set a €119.00 ($138.37) price target on shares of Merck KGaA and gave the company a “buy” rating in a research note on Monday, July 31st. S&P Global set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the company a “buy” rating in a research note on Thursday, August 3rd. equinet AG set a €112.00 ($130.23) price target on shares of Merck KGaA and gave the company a “buy” rating in a research note on Thursday, August 31st. BNP Paribas set a €116.00 ($134.88) price target on shares of Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, September 6th. Finally, Warburg Research set a €115.00 ($133.72) price target on shares of Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, September 6th. Thirteen analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of €108.61 ($126.29).

Shares of Merck KGaA (MRK) opened at €89.79 ($104.41) on Friday. Merck KGaA has a 12 month low of €89.00 ($103.49) and a 12 month high of €115.00 ($133.72).

WARNING: This story was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/11/12/merck-kgaa-mrk-pt-set-at-99-00-by-deutsche-bank-ag.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply